The Journal of Pediatrics
Volume 152, Issue 3 , Pages 394-399.e2 , March 2008

Modafinil Improves Symptoms of Attention-Deficit/Hyperactivity Disorder across Subtypes in Children and Adolescents

  • Joseph Biederman, MD

      Affiliations

    • From the Pediatric Psychopharmacology Unit, Massachusetts General Hospital, Boston, MA
    • Dr Biederman receives research support from the following sources: Shire, Eli Lilly, Pfizer, McNeil, Abbott, Bristol-Myers-Squibb, New River Pharmaceuticals, Cephalon, Janssen, Neurosearch, Stanley Medical Institute, Novartis, Lilly Foundation, Prechter Foundation, National Institutes of Mental Health, National Institute of Child Health and Human Development, and National Institute on Drug Abuse. Dr Biederman is a speaker for the following speakers’ bureaus: Shire, Lilly, McNeil, Cephalon, UCB Pharma, and Novartis. Dr Biederman is on the advisory board of the following pharmaceutical companies: Eli Lilly, Shire, McNeil, Janssen, Novartis, and Cephalon.
    • Corresponding Author InformationReprint requests: Joseph Biederman, MD, Massachusetts General Hospital, Pediatric Psychopharmacology Unit, Yawkey Center for Outpatient Care, YAW-6A-6900, 32 Fruit St., Boston, MA 02114.
    • ,
  • Steven R. Pliszka, MD

      Affiliations

    • University of Texas Health Science Center, San Antonio, TX.
    • Dr Pliszka receives research support from Eli Lilly and Cephalon and is a speaker for speakers’ bureaus sponsored by Shire and McNeil.

Received 12 June 2006 ,Revised 20 June 2007 ,Accepted 27 July 2007.

References 

  1. Faraone SV, Sergeant J, Gillberg C, Biederman J. The worldwide prevalence of ADHD: is it an American condition?. World Psychiatry. 2003;2:104–113
  2. Lahey BB, Applegate B, McBurnett K, Biederman J, Greenhill L, Hynd GW, et al. DSM-IV field trials for attention deficit hyperactivity disorder in children and adolescents. Am J Psychiatry. 1994;151:1673–1685
  3. Graetz BW, Sawyer MG, Hazell PL, Arney F, Baghurst P. Validity of DSM-IVADHD subtypes in a nationally representative sample of Australian children and adolescents. J Am Acad Child Adolesc Psychiatry. 2001;40:1410–1417
  4. Woo BS, Rey JM. The validity of the DSM-IV subtypes of attention-deficit/hyperactivity disorder. Aust N Z J Psychiatry. 2005;39:344–353
  5. Escobar R, Soutullo C, San Sebastian J, Fernandez E, Julian I, Lahortiga F. Atomoxetine safety and efficacy in children with attention deficit/hyperactivity disorder (ADHD): initial phase of 10-week treatment in a relapse prevention study with a Spanish sample. Actas Esp Psiquiatr. 2005;33:26–32
  6. Hoare P, Remschmidt H, Medori R, Ettrich C, Rothenberger A, Santosh P, et al. 12-month efficacy and safety of OROS MPH in children and adolescents with attention-deficit/hyperactivity disorder switched from MPH. Eur Child Adolesc Psychiatry. 2005;14:305–309
  7. O’Driscoll GA, Depatie L, Holahan AL, Savion-Lemieux T, Barr RG, Jolicoeur C, et al. Executive functions and methylphenidate response in subtypes of attention-deficit/hyperactivity disorder. Biol Psychiatry. 2005;57:1452–1460
  8. Scammell TE, Estabrooke IV, McCarthy MT, Chemelli RM, Yanagisawa M, Miller MS, et al. Hypothalamic arousal regions are activated during modafinil-induced wakefulness. J Neurosci. 2000;20:8620–8628
  9. Lin JS, Hou Y, Jouvet M. Potential brain neuronal targets for amphetamine-, methylphenidate-, and modafinil-induced wakefulness, evidenced by c-fos immunocytochemistry in the cat. Proc Natl Acad Sci U S A. 1996;93:14128–14133
  10. Baumann CR, Bassetti CL. Hypocretins (orexins) and sleep-wake disorders. Lancet Neurol. 2005;4:673–682
  11. Konrad K, Neufang S, Hanisch C, Fink GR, Herpertz-Dahlmann B. Dysfunctional attentional networks in children with attention deficit/hyperactivity disorder: evidence from an event-related functional magnetic resonance imaging study. Biol Psychiatry. 2006;59:643–651
  12. Zang YF, Jin Z, Weng XC, Zhang L, Zeng YW, Yang L, et al. Functional MRI in attention-deficit hyperactivity disorder: evidence for hypofrontality. Brain Dev. 2005;27:544–550
  13. Swanson JM, Greenhill LL, Lopez FA, Sedillo A, Earl CQ, Jiang J, et al. Modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, fixed-dose study followed by abrupt discontinuation. J Clin Psychiatry. 2006;67:137–147
  14. Biederman J, Swanson JM, Wigal SB, Kratochvil CJ, Boellner SW, Earl CQ, et al. Efficacy and safety of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, flexible-dose study. Pediatrics. 2005;116:e777–e784
  15. Greenhill LL, Biederman J, Boellner SW, Rugino TA, Sangal RB, Earl CQ, et al. A randomized, double-blind, placebo-controlled study of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2006;45:503–511
  16. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th Edition. Washington, DC: American Psychiatric Association; 1994;
  17. Guy W. ECDEU Assessment Manual for Psychopharmacology, Revised (US Department of Health, Education, and Welfare Publication (ADM) 76-338). Rockville, MD: National Institute of Mental Health; 1976;
  18. DuPaul GJ, Power TJ, Anastopoulos AD, Reid R. ADHD Rating Scale-IV: Checklists, Norms, and Clinical Interpretation. New York: Guilford Press; 1998;
  19. Conners CK. Conners’ Parent Rating Scales-Revised: Short Form (CPRS-R:S). Tonawanda, NY: Multi-Health Systems; 1997;
  20. Booth JH. Conners’ Rating Scales–revised. In: Gale Encyclopedia of Mental Disorders. Detroit, MI: The Gale Group, Inc; 2003;Available at: http://www.healthline.com/galecontent/conners-rating-scales-revised. Accessed May 15, 2007
  21. Wigal SB, Biederman J, Swanson JM, Yang R, Greenhill LL. Efficacy and safety of modafinil film-coated tablets in children and adolescents with or without prior stimulant treatment for attention-deficit/hyperactivity disorder: pooled analysis of 3 randomized, double-blind, placebo-controlled studies. Primary Care Companion J Clin Psychiatry. 2006;8:352–360
  22. Gaub M, Carlson CL. Behavioral characteristics of DSM-IV ADHD subtypes in a school-based population. J Abnorm Child Psychol. 1997;25:103–111
  23. Faraone SV, Biederman J, Weber W, Russell RL. Psychiatric, neuropsychological, and psychosocial features of DSM-IV subtypes of attention-deficit/hyperactivity disorder: results from a clinically referred sample. J Am Acad Child Adolesc Psychiatry. 1998;37:185–193
  24. Nolan EE, Gadow KD, Sprafkin J. Teacher reports of DSM-IV ADHD, ODD, and CD symptoms in schoolchildren. J Am Acad Child Adolesc Psychiatry. 2001;40:241–249
  25. Baumgaertel A, Wolraich ML, Dietrich M. Comparison of diagnostic criteria for attention deficit disorders in a German elementary school sample. J Am Acad Child Adolesc Psychiatry. 1995;34:629–638
  26. Eiraldi RB, Power TJ, Nezu CM. Patterns of comorbidity associated with subtypes of attention-deficit/hyperactivity disorder among 6- to 12-year-old children. J Am Acad Child Adolesc Psychiatry. 1997;36:503–514
  27. Levy F, Hay DA, Bennett KS, McStephen M. Gender differences in ADHD subtype comorbidity. J Am Acad Child Adolesc Psychiatry. 2005;44:368–376
  28. Wolraich ML, Hannah JN, Pinnock TY, Baumgaertel A, Brown J. Comparison of diagnostic criteria for attention-deficit hyperactivity disorder in a county-wide sample. J Am Acad Child Adolesc Psychiatry. 1996;35:319–324
  29. Spencer TJ, Abikoff HB, Connor DF, Biederman J, Pliszka SR, Boellner S, et al. Efficacy and safety of mixed amphetamine salts extended-release (Adderall XR) in the management of oppositional defiant disorder with or without comorbid attention-deficit/hyperactivity disorder in school-aged children and adolescents: a 4-week, multicenter, randomized, double-blind, parallel-group, placebo-controlled, forced-dose-escalation study. Clin Ther. 2006;28:402–418
  30. Aman MG, Binder C, Turgay A. Risperidone effects in the presence/absence of psychostimulant medicine in children with ADHD, other disruptive behavior disorders, and subaverage IQ. J Child Adolesc Psychopharmacol. 2004;14:243–254
  31. Kopecky H, Chang HT, Klorman R, Thatcher JE, Borgstedt AD. Performance and private speech of children with attention-deficit/hyperactivity disorder while taking the Tower of Hanoi test: effects of depth of search, diagnostic subtype, and methylphenidate. J Abnorm Child Psychol. 2005;33:625–638

 The research detailed in this manuscript was funded by Cephalon, Inc.

PII: S0022-3476(07)00748-2

doi: 10.1016/j.jpeds.2007.07.052

The Journal of Pediatrics
Volume 152, Issue 3 , Pages 394-399.e2 , March 2008

Article Tools

* Image Usage & Resolution